Xeris Biopharma Holdings (XERS) Share-based Compensation (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Share-based Compensation for 7 consecutive years, with $191000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation fell 86.85% year-over-year to $191000.0; the trailing twelve-month figure through Jun 2026 stood at $30.1 million (up 52.03% YoY), and the FY2025 full-year result was $22.4 million, up 21.8% from the prior year.
• Share-based Compensation retreated to $191000.0 in Q2 2026 per XERS's latest filing, from $17.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $20.0 million in Q2 2023 and bottomed at $191000.0 in Q2 2026.
• Historically, Share-based Compensation has averaged $6.0 million across 5 years, with a median of $3.8 million in 2024.
• The widest YoY moves for Share-based Compensation: up 112.77% in 2026, down 86.85% in 2026.
• Over 5 years, Share-based Compensation stood at $2.8 million in 2022, then advanced by 0.04% to $2.8 million in 2023, then increased by 29.92% to $3.6 million in 2024, then surged by 46.65% to $5.3 million in 2025, then slumped by 96.38% to $191000.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $191000.0, $17.0 million, and $5.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.